Structure Therapeutics Inc. (NASDAQ:GPCR) Shares Acquired by XTX Topco Ltd

XTX Topco Ltd increased its position in Structure Therapeutics Inc. (NASDAQ:GPCR) by 100.9% in the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 11,938 shares of the company’s stock after purchasing an additional 5,997 shares during the period. XTX Topco Ltd’s holdings in Structure Therapeutics were worth $524,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Bank of Montreal Can bought a new position in Structure Therapeutics during the 2nd quarter worth approximately $1,064,000. Lighthouse Investment Partners LLC acquired a new stake in shares of Structure Therapeutics during the 2nd quarter valued at approximately $1,178,000. Vestal Point Capital LP lifted its stake in Structure Therapeutics by 105.4% during the third quarter. Vestal Point Capital LP now owns 1,150,000 shares of the company’s stock worth $50,474,000 after purchasing an additional 590,000 shares during the last quarter. abrdn plc boosted its holdings in Structure Therapeutics by 132.7% in the third quarter. abrdn plc now owns 217,083 shares of the company’s stock worth $9,528,000 after purchasing an additional 123,789 shares during the period. Finally, Bellevue Group AG increased its stake in Structure Therapeutics by 13.0% during the third quarter. Bellevue Group AG now owns 629,758 shares of the company’s stock valued at $27,640,000 after purchasing an additional 72,437 shares during the last quarter. 91.78% of the stock is owned by institutional investors.

Structure Therapeutics Price Performance

GPCR opened at $31.25 on Friday. Structure Therapeutics Inc. has a 12 month low of $26.61 and a 12 month high of $62.74. The stock’s 50 day moving average price is $36.56 and its 200 day moving average price is $39.22. The stock has a market cap of $1.79 billion, a P/E ratio of -42.81 and a beta of -3.41.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the stock. HC Wainwright assumed coverage on shares of Structure Therapeutics in a research report on Wednesday, December 4th. They issued a “buy” rating and a $80.00 price target on the stock. Morgan Stanley initiated coverage on Structure Therapeutics in a research note on Monday, September 23rd. They issued an “overweight” rating and a $118.00 target price for the company. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $65.00 target price on shares of Structure Therapeutics in a report on Monday, September 23rd. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $85.67.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.